The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Tue, 08.04.2025
Walgreens Boots Alliance
US9314271084
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced financial results for the second quarter of fiscal 2025, which ended February 28, 2025.
Chief Executive Officer Tim Wentworth said:
“Second quarter results reflect disciplined cost management and improvement in U.S. Healthcare, which were partially offset by weaker front-end results in...
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. (“Walgreens” or “the Company”) (NASDAQ: WBA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Comm...
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between April 2, 2020 and January 16, 2025. Walgreens describes itself as a “healthcare, pharmacy, and retail company.”
For more information, submit a ...
The Ademi Firm is investigating Walgreens (NASDAQ: WBA) for possible breaches of fiduciary duty and other violations of law in its transaction with Sycamore.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
I...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Walgreens Boots Alliance (NASDAQ: WBA) to Sycamore Partners is fair to Walgreens shareholders. Under the terms of the proposed transaction, Walgreens shareholders will receive $11.45 per share in cash at closing and one non-transferable right to receive up to $3.00...
Walgreens Boots Alliance (NASDAQ: WBA) (the "Company" or “WBA”) today announced that it has entered into a definitive agreement to be acquired by an entity affiliated with Sycamore Partners (“Sycamore”), a private equity firm specializing in retail, consumer and distribution-related investments. The total value of the transaction represents up to ...
The Walgreens Flu Index has tracked its fourth consecutive week of increasing flu activity, with most states across the country experiencing high levels of flu. Overall, U.S. flu activity over the last four weeks is significantly higher when compared to the same time last year – flu activity from the week ending February 8, 2025, was 204% higher c...
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. (“Walgreens” or “the Company”) (NASDAQ: WBA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants...
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) common stock between April 2, 2020 and January 16, 2025, inclusive (the “Class Period”), have until March 31, 2025 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Klein v. Walgreens Boot...
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) has agreed to the early settlement of certain prepaid variable share forward transactions it had previously entered into with various financial institutions, with respect to shares of Cencora, Inc. (NYSE: COR). Under these transactions, the Company had previously received cash payments in an aggregate a...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .